|
Sep 03 2024
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 29 2024
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
|
Aug 08 2024
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
|
|
Aug 01 2024
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
|
|
Jul 09 2024
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
|
|
Jun 28 2024
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
|
|
Jun 27 2024
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
|
|
Jun 27 2024
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
|
|
Jun 25 2024
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 13 2024
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
|
|
Jun 13 2024
Gain Therapeutics Announces Proposed Public Offering
|
|
May 30 2024
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
|
|
May 14 2024
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
|
|
Apr 24 2024
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
|
Apr 08 2024
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
|
|
Apr 01 2024
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
|
|
Mar 26 2024
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
|
|
Mar 15 2024
Gain Therapeutics to Present at Public Ventures Discovery Day
|
|
Mar 05 2024
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
|
|
Feb 27 2024
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
|
Feb 14 2024
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
|
|
Feb 06 2024
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
|
Feb 06 2024
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
|
Jan 30 2024
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
|
|
Jan 01 2024
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
|
